These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 12878536)

  • 1. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria.
    Ouderkirk JP; Nord JA; Turett GS; Kislak JW
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2659-62. PubMed ID: 12878536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections.
    Sobieszczyk ME; Furuya EY; Hay CM; Pancholi P; Della-Latta P; Hammer SM; Kubin CJ
    J Antimicrob Chemother; 2004 Aug; 54(2):566-9. PubMed ID: 15269195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.
    Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK
    Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
    Vardakas KZ; Falagas ME
    Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen.
    Okoduwa A; Ahmed N; Guo Y; Scipione MR; Papadopoulos J; Eiras DP; Dubrovskaya Y
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy.
    Crusio R; Rao S; Changawala N; Paul V; Tiu C; van Ginkel J; Chapnick E; Kupfer Y
    Scand J Infect Dis; 2014 Jan; 46(1):1-8. PubMed ID: 24206450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
    Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use.
    Mendes CA; Cordeiro JA; Burdmann EA
    Ann Pharmacother; 2009 Dec; 43(12):1948-55. PubMed ID: 19887593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
    Zavascki AP; Goldani LZ; Li J; Nation RL
    J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study.
    Siddiqui NU; Qamar FN; Jurair H; Haque A
    BMC Infect Dis; 2014 Nov; 14():626. PubMed ID: 25430979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colistin and polymyxin B in critical care.
    Michalopoulos A; Falagas ME
    Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk factors for acute kidney injury in patients treated with polymyxin B experience from 139 cases at a tertiary university hospital in Colombia].
    Osorio J; Barreto J; Samboni CF; Cándelo LA; Álvarez LC; Benavidez S; Téllez RP; Santofimio D; Ramos JA; Gómez CA
    Rev Chilena Infectol; 2017 Feb; 34(1):7-13. PubMed ID: 28394975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
    Evans ME; Feola DJ; Rapp RP
    Ann Pharmacother; 1999 Sep; 33(9):960-7. PubMed ID: 10492501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Polymyxins - review with emphasis on nephrotoxicity].
    Mendes CA; Burdmann EA
    Rev Assoc Med Bras (1992); 2009; 55(6):752-9. PubMed ID: 20191233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: An evaluation of the current evidence.
    Falagas ME; Kyriakidou M; Voulgaris GL; Vokos F; Politi S; Kechagias KS
    J Glob Antimicrob Resist; 2021 Mar; 24():342-359. PubMed ID: 33486122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies.
    Oliota AF; Penteado ST; Tonin FS; Fernandez-Llimos F; Sanches AC
    Diagn Microbiol Infect Dis; 2019 May; 94(1):41-49. PubMed ID: 30635223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients.
    Ismail B; Shafei MN; Harun A; Ali S; Omar M; Deris ZZ
    J Microbiol Immunol Infect; 2018 Dec; 51(6):763-769. PubMed ID: 28716359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.
    Huang J; Tang YQ; Sun JY
    Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria.
    Falagas ME; Kasiakou SK; Kofteridis DP; Roditakis G; Samonis G
    Eur J Clin Microbiol Infect Dis; 2006 Sep; 25(9):596-9. PubMed ID: 16955249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.